SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novartis MS drug remibrutinib seen advantaged on liver safety

Citi analysts said Novartis’s late-stage multiple sclerosis studies for remibrutinib reported no liver-safety signals, potentially differentiating it from a Roche rival drug based on safety profile.

NOT

Citi analysts said Novartis’s new multiple sclerosis drug may stand apart from a rival product Roche Holding is developing because of its safety profile. Novartis said it saw no liver-safety signals in late-stage studies of remibrutinib in multiple sclerosis, while Roche…

Related stories